

REMARKS

Status of claims

Claims 1 to 18 are currently pending in the present application and claims 1 to 17 are canceled herein. Therefore, only claim 18 will remain pending after the present amendments are entered.

Claims 1 to 14 stand rejected under 35 U.S.C. § 112, second paragraph, as allegedly indefinite for using the term “metabolite.” Claims 1 to 17 are also provisionally rejected under the doctrine of obviousness-type double patenting as being allegedly unpatentable over claims 1 to 8 and 10 of copending United States Patent Application No. 11/003,952. Finally, Applicants wish to thank the Examiner for indicating that claim 18 is allowable.

Rejection of claims 1 to 14 under 35 U.S.C. § 112, second paragraph

Claims 1 to 14 stand rejected under 35 U.S.C. § 112, second paragraph, as allegedly indefinite for using the term “metabolite.” In order to advance prosecution, and without conceding to the merits of this rejection, Applicants have canceled claims 1 to 14 in the present amendment. Therefore, this rejection is moot and Applicants respectfully ask that it be withdrawn.

Obviousness-type double patenting

Claims 1 to 17 are also provisionally rejected under the doctrine of obviousness-type double patenting as being allegedly unpatentable over claims 1 to 8 and 10 of copending United States Patent Application No. 11/003,952. Applicants traverse this rejection with respect to all claims. But, in order to advance prosecution, and without conceding to the merits of this rejection, Applicants have canceled claims 1 to 17 in the present amendment. Therefore, this rejection is moot and Applicants respectfully ask that it be withdrawn.

Applicants respectfully submit that the present amendments place the application in a form for immediate allowance.

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time, for which Applicants hereby petition, please charge such fees to Deposit Account No. 500329.

Response to Office Action in U.S. Patent Application No. 10/728,602
Confirmation No. 9761
Attorney Docket No. PC19090B/AG 0136-02

Respectfully submitted,

Date: September 20, 2006

/Jeffrey H. Tidwell/
Jeffrey H. Tidwell
Attorney For Applicants
Registration No. 47,995

Pfizer Inc.
Patent Department
10555 Science Center Drive
San Diego, California 92121
Phone: (858) 638-3877
Fax: (858) 678-8233